PPHVanEck Pharmaceutical ETF
Fund Description
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
-
Fund Ticker
PPH -
Exchange
NASDAQ -
Inception Date
12/20/2011 -
ETF Structure
Physical -
Administrator
Van Eck Associates -
Index Ticker
MVPPHTR -
Index Rebalancing
Quarterly
as of 03/24/23
-
30-Day SEC Yield1
1.84% -
Total Net Assets
$369.2M -
Number of Holdings
25 -
Options
Available -
Gross Expense Ratio2
0.36% -
Net Expense Ratio/TER2
0.36% -
Distribution Frequency
Quarterly -
Next Distribution Date
03/31/2023
Key Documents and Links
Fund Highlights
- Highly Liquid Companies
Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders
Index methodology favors the largest companies in the industry
- Global Scope
Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
Trading Information
-
Fund Ticker
PPH -
Index Total Return Ticker
MVPPHTR -
NAV
PPHNV -
Intraday NAV (IIV)4
PPHIV -
Shares Outstanding
4,888,138 -
Estimated Cash
PPHEU -
Total Cash
PPHTC -
CUSIP
92189F692 -
ISIN
US92189F6925
Fees and Expenses2
-
Management Fee
0.35% -
Other Expenses
0.01% -
Acquired Fund Fees and Expenses
-- -
Gross Expense Ratio
0.36% -
Fee Waivers and
--
Expense Reimbursement -
Net Expense Ratio/TER2
0.36%
2 Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2024.
Investment Professionals
Peter Liao, CFA
- Portfolio Manager and Head of Equity ETFs
- Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
- Joined VanEck in 2005
- CFA charterholder; member of the CFA Society New York
- BA, Mathematics and Economics, New York University
Griffin Driscoll
- Analyst for Equity ETFs
- Joined VanEck in 2018
- Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
- BS, Finance, Providence College
Ralph Lasta
- Analyst for Equity ETFs
- Joined VanEck in 2019
- Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
- BS, Accounting, Hunter College
Performance History: Average Annual Total Returns* (%)
1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 12/20/11 |
|
---|---|---|---|---|---|---|---|---|
PPH (NAV) | -3.48 | -1.62 | -2.72 | 1.45 | 10.45 | 7.42 | 7.91 | 9.02 |
PPH (Share Price) | -3.43 | -1.49 | -2.69 | 1.49 | 10.47 | 7.41 | 7.90 | 9.11 |
MVPPHTR (Index) | -3.49 | -1.75 | -2.86 | 1.24 | 10.14 | 7.18 | 7.79 | 8.90 |
Performance Differential (NAV - Index) | 0.01 | 0.13 | 0.14 | 0.21 | 0.31 | 0.24 | 0.12 | 0.12 |
1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 12/20/11 |
|
---|---|---|---|---|---|---|---|---|
PPH (NAV) | 1.13 | 16.46 | 2.64 | 2.64 | 8.50 | 7.50 | 8.99 | 9.43 |
PPH (Share Price) | 1.23 | 16.44 | 2.60 | 2.60 | 8.52 | 7.51 | 8.99 | 9.52 |
MVPPHTR (Index) | 1.15 | 16.44 | 2.54 | 2.54 | 8.14 | 7.24 | 8.89 | 9.32 |
Performance Differential (NAV - Index) | -0.02 | 0.02 | 0.10 | 0.10 | 0.36 | 0.26 | 0.10 | 0.11 |
Top 10 Holdings (%) as of 02/28/23
Daily HoldingsHolding Name |
Ticker
|
Shares
|
Market Value (US$) |
% of Net Assets |
---|---|---|---|---|
Johnson & Johnson |
JNJ US
|
193,282
|
29,622,399 | 7.40 |
Novo Nordisk A/S |
NVO US
|
164,274
|
23,160,991 | 5.79 |
Abbvie Inc |
ABBV US
|
140,801
|
21,669,274 | 5.42 |
Merck & Co Inc |
MRK US
|
201,854
|
21,444,969 | 5.36 |
Zoetis Inc |
ZTS US
|
123,242
|
20,581,414 | 5.14 |
Haleon Plc |
HLN US
|
2,533,036
|
19,960,324 | 4.99 |
Astrazeneca Plc |
AZN US
|
298,820
|
19,477,088 | 4.87 |
Takeda Pharmaceutical Co Ltd |
TAK US
|
1,260,491
|
19,348,537 | 4.84 |
Eli Lilly & Co |
LLY US
|
62,136
|
19,337,966 | 4.83 |
Novartis Ag |
NVS US
|
224,290
|
18,867,275 | 4.72 |
Top 10 Total (%) | 53.36 |
Country Weightings (%)
as of 02/28/23
Country | % of Net Assets |
---|---|
● United States | 61.99 |
● United Kingdom | 14.16 |
● Denmark | 5.79 |
● Japan | 4.84 |
● Switzerland | 4.72 |
● France | 4.52 |
● Israel | 3.95 |
● Other/Cash | 0.04 |
Sector Weightings (%)
as of 02/28/23
Sector | % of Net Assets |
---|---|
● Health Care | 94.97 |
● Consumer Staples | 4.99 |
● Other/Cash | 0.04 |